Loading…
Based on limited metadata, the FDA issued a warning letter to Humaworm on April 20, 2020, regarding drug products. Without access to the full warning letter text or specific subject line, the precise nature of the violations cannot be determined from the available information. The letter falls under FDA's drug product regulatory authority, though the specific issuing office is not identified in the metadata provided. To understand the complete regulatory concerns and required corrective actions, review of the full warning letter would be necessary.